Skip to content

A confirmation study of bowel control effect by consumption of the test food

A confirmation study of bowel control effect by consumption of the test food - A confirmation study of bowel control effect by consumption of the test food

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039591
Enrollment
40
Registered
2021-02-28
Start date
2020-02-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Intake one capsule of the test food a day for two weeks Intake one capsule of the control food a day for two weeks

Sponsors

CPCC Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Healthy males and females aged over 20 to under 65 when informed consent. 2)Subjects who are defecated tendency (their defecation frequency are 3 to 5 times a week) 3)Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.

Exclusion criteria

Exclusion criteria: 1) Subjects who constantly eat seaweeds like simmered laver in sweetened soy sauce etc., or subjects who can't restrict eat them during test period. 2) Subjects who are given continuous treatment by taking medicines. 3) Subjects who intaking Food for Specified Health Uses (FOSHU), food with function claims and/or health food, those having possibility of defecation improvement or soft stool improvement, more than three days a week. 4) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period. 5) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). 6) Subjects who excessive alcohol intake. 7) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. 8) Subjects who have previous medical history of drug and/or food allergy. 9) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. 10) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. 11) Males who donated over 400mL blood and/or blood components within the last three months to the current study. 12) Females who donated over 400mL blood and/or blood components within the last four months to the current study. 13) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 14) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 15) Others who have been determined ineligible by principal investigator or sub-investigator.

Design outcomes

Primary

MeasureTime frame
Defecation status (defecation frequency, defecation days, Bristol Stool Sclae)

Secondary

MeasureTime frame
*Defecation status (smell of stool, color of stool, volume of stool, exhilaration by defecation, abdominal symptoms) * Analysis of organic acids content in stool * Stool properties (pH of stool, water content of stool) * Analysis of stool ammonia * Intestinal microbiota (Analysis by sequencing of amplicons) * Incidence of adverse events and of side effects

Countries

Japan

Contacts

Public ContactMitsuhiro Fujimoto

CPCC Company Limited Planning & Sales Department

cpcc-contact@cpcc.co.jp03-5297-3112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026